Integrated vs. Modular CDMO Strategy for Advanced Therapies
November 18, 2026
The advanced therapy sector has historically operated within a highly fragmented manufacturing ecosystem. As cell and gene...
Read more →I've been working in DNA-based medicine long enough to have spent most of my career defending plasmid to regulatory bodies, knowing very well it wasn't the perfect starting...
Read More →November 18, 2026
The advanced therapy sector has historically operated within a highly fragmented manufacturing ecosystem. As cell and gene...
Read more →October 19, 2026
I could talk about this for hours, but the thing that frustrates me most is how short our collective memory has been. It's been...
Read more →September 09, 2026
Merck and Moderna have reported positive Phase 3 data. The vaccine, when tested with an existing immunotherapy, significantly...
Read more →August 28, 2026
For as long as nucleic acid medicine has existed, developers have structured their programs around a bottleneck that everyone in...
Read more →August 26, 2026
Kate Broderick, PhD, Chief Scientific and Innovation Officer at Artis BioSolutions, joined a TechCon panel on what the next era...
Read more →August 12, 2026
Over the four posts in this series, we have built a complete framework for evaluating a CDMO for advanced therapy development. We...
Read more →July 20, 2026
In the first three posts in this series, we covered the manufacturing landscape for advanced therapies, the importance of...
Read more →July 14, 2026
In the previous post, we covered the two structural criteria that most reliably distinguish a translational development partner...
Read more →July 06, 2026
In the first post in this series, we looked at the manufacturing landscape for advanced therapies and what the FDA data tells us...
Read more →